Cardiovascular Risk Stratification and Management in Pre-Diabetes

  • Kristine Færch
  • Dorte Vistisen
  • Nanna Borup Johansen
  • Marit Eika Jørgensen
Macrovascular Complications in Diabetes (L Perreault, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Macrovascular Complications in Diabetes

Abstract

Prediabetes, covering individuals with impaired fasting glycemia, impaired glucose tolerance, or high-risk HbA1c levels, is associated with a ∼20 % increased risk of developing cardiovascular disease (CVD) compared with normoglycemic individuals. It is well-known that lifestyle or pharmacologic interventions can prevent diabetes in prediabetic people; however, the evidence is less clear regarding prevention of CVD. Most diabetes prevention trials have failed to show beneficial effects on CVD morbidity and mortality despite significant improvements of CVD risk factors in individuals with prediabetes. Another challenge is how to estimate CVD risk in prediabetic people. In general, prediction models for CVD do not take glucose levels or prediabetes status into account, thereby underestimating CVD risk in these high-risk individuals. More evidence within risk stratification and management of CVD risk in prediabetes is needed in order to recommend useful and effective strategies for early prevention of CVD.

Keywords

Prediabetes Impaired fasting glucose Impaired glucose tolerance Fasting glucose 2-hour glucose HbA1c Cardiovascular disease Risk prediction Risk stratification Prevention Management 

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    International Diabetes Federation. Diabetes Atlas, 5th Edition Update for 2012. 2012.Google Scholar
  2. 2.
    The Emerging Risk Factors Collaboration. Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med. 2011;364:829–41.PubMedCentralCrossRefGoogle Scholar
  3. 3.
    Tabak AG, Herder C, Rathmann W, Brunner EJ, Kivimaki M. Prediabetes: a high-risk state for diabetes development. Lancet. 2012;379:2279–90.PubMedCentralPubMedCrossRefGoogle Scholar
  4. 4.
    Perreault L, Færch K. Approaching pre-diabetes. J Diabetes Complications. 2013; [Epub ahead of print].Google Scholar
  5. 5.•
    American Diabetes Association Standards of Medical Care in Diabetes - 2014. Diabetes Care. 2014;7:S14–80. These guidelines represent the most up-to-date American recommendations on management of diabetes and prediabetes. Google Scholar
  6. 6.
    Tuomilehto J, Lindström J, Eriksson JG, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med. 2001;344:1343–50.PubMedCrossRefGoogle Scholar
  7. 7.
    Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346:393–403.PubMedCrossRefGoogle Scholar
  8. 8.
    De Vegt F, Dekker JM, Jager A, et al. Relation of impaired fasting and postload glucose with incident type 2 diabetes in a Dutch population: the Hoorn study. JAMA. 2001;285:2109–13.PubMedCrossRefGoogle Scholar
  9. 9.
    Mooy JM, Grootenhuis PA, de Vries H, et al. Intra-individual variation of glucose, specific insulin and proinsulin concentrations measured by two oral glucose tolerance tests in a general Caucasian population: the Hoorn Study. Diabetologia. 1996;39:298–305.PubMedCrossRefGoogle Scholar
  10. 10.
    Hulmán A, Færch K, Vistisen D, et al. Effect of time of day and fasting duration on measures of glycaemia: analysis from the Whitehall II Study. Diabetologia. 2013;56:294–7.PubMedCrossRefGoogle Scholar
  11. 11.
    World-Health, Organization and International Diabetes Federation. Definition and diagnosis of diabetes mellitus and intermediate hyperglycaemia: report of a WHO/IDF consultation. Geneva: World Health Organization; 2006.Google Scholar
  12. 12.
    The International Expert Committee International Expert Committee Report on the Role of the A1C Assay in the Diagnosis of Diabetes. Diabetes Care. 2009;32:1327–34.Google Scholar
  13. 13.
    Alberti KGMM, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. Report of a WHO consultation. Diabetic Med. 1998;15:539–53.PubMedCrossRefGoogle Scholar
  14. 14.
    World Health Organization. Use of Glycated Haemoglobin (HbA1c) in the Diagnosis of Diabetes Mellitus. Abbreviated Report of a WHO Consultation. Geneva, Switzerland: WHO Press; 2011. p. 1–25.Google Scholar
  15. 15.
    Borch-Johnsen K, Colagiuri S, Balkau B, et al. Creating a pandemic of prediabetes: the proposed new diagnostic criteria for impaired fasting glycaemia. Diabetologia. 2004;47:1396–402.PubMedCrossRefGoogle Scholar
  16. 16.
    Xu Y, Wang L, He J. Prevalence and control of diabetes in Chinese adults. JAMA. 2013;310:948–59.PubMedCrossRefGoogle Scholar
  17. 17.
    Færch K, Vistisen D. Response to Xu et al. “Prevalence and Control of Diabetes in Chinese Adults”. JAMA. 2014;311(2):200.Google Scholar
  18. 18.••
    Ford ES, Zhao G, Li C. Pre-diabetes and the risk for cardiovascular disease: a systematic review of the evidence. J Am Coll Cardiol. 2010;55:1310–7. This review and meta-analysis shows that both impaired fasting glucose and impaired glucose tolerance are associated with ∼20 % increased risk of developing cardiovascular disease.PubMedCrossRefGoogle Scholar
  19. 19.
    DECODE Study Group Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria. Arch Intern Med. 2001;161:397–405.Google Scholar
  20. 20.
    Tominaga M, Eguchi H, Manaka H, Igarashi K, Kato T, Sekikawa A. Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. The Funagata Diabetes Study. Diabetes Care. 1999;22:920–4.PubMedCrossRefGoogle Scholar
  21. 21.
    Barr ELM, Zimmet PZ, Welborn TA, et al. Risk of cardiovascular and all-cause mortality in individuals with diabetes mellitus, impaired fasting glucose, and impaired glucose tolerance: the Australian Diabetes, Obesity, and Lifestyle Study (AusDiab). Circulation. 2007;116:151–7.PubMedCrossRefGoogle Scholar
  22. 22.
    Sarwar N, Gao P, Seshasai SR, et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet. 2010;375:2215–22.PubMedCrossRefGoogle Scholar
  23. 23.•
    Qiao Q, Pyorala K, Pyorala M, et al. Two-hour glucose is a better risk predictor for incident coronary heart disease and cardiovascular mortality than fasting glucose. Eur Heart J. 2002;23:1267–75. This study shows that 2-hour glucose independent of fasting glucose is a significant predictor of cardiovascular disease, whereas fasting glucose does not have an independent effect over 2-hour glucose.PubMedCrossRefGoogle Scholar
  24. 24.
    Selvin E, Steffes MW, Zhu H, et al. Glycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults. N Engl J Med. 2010;362:800–11.PubMedCentralPubMedCrossRefGoogle Scholar
  25. 25.
    Barr EL, Boyko EJ, Zimmet PZ, Wolfe R, Tonkin AM, Shaw JE. Continuous relationships between non-diabetic hyperglycaemia and both cardiovascular disease and all-cause mortality: the Australian Diabetes, Obesity, and Lifestyle (AusDiab) study. Diabetologia. 2009;52:415–24.PubMedCrossRefGoogle Scholar
  26. 26.••
    Kodama S, Saito K, Tanaka S, et al. Fasting and post-challenge glucose as quantitative cardiovascular risk factors: a meta-analysis. J Atheroscler Thromb. 2012; [Epub ahead of print]. This review and meta-analysis shows that both fasting and postload glucose is associated with cardiovascular disease, but the effect of postload glucose is larger than that of fasting glucose. Google Scholar
  27. 27.
    Sarwar N, Aspelund T, Eiriksdottir G, et al. Markers of dysglycaemia and risk of coronary heart disease in people without diabetes: Reykjavik prospective study and systematic review. PLoS Med. 2010;7:e1000278.PubMedCentralPubMedCrossRefGoogle Scholar
  28. 28.
    Hyvarinen M, Tuomilehto J, Laatikainen T, et al. The impact of diabetes on coronary heart disease differs from that on ischaemic stroke with regard to the gender. Cardiovasc Diabetology. 2009;8:17.CrossRefGoogle Scholar
  29. 29.
    Stranges S, Guallar E. Cardiovascular disease prevention in women: a rapidly evolving scenario. Nutr Metabol Cardiovasc Dis. 2012;22:1013–8.CrossRefGoogle Scholar
  30. 30.
    Barrett-Connor EL, Cohn BA, Wingard DL, Edelstein SL. Why is diabetes mellitus a stronger risk factor for fatal ischemic heart disease in women than in men? The Rancho Bernardo study. JAMA. 1991;265:627–31.PubMedCrossRefGoogle Scholar
  31. 31.
    Penno G, Solini A, Bonora E, et al. Gender differences in cardiovascular disease risk factors, treatments and complications in patients with type 2 diabetes: the RIACE Italian multicentre study. J Intern Med. 2013;274:176–91.PubMedCrossRefGoogle Scholar
  32. 32.
    Huxley R, Barzi F, Woodward M. Excess risk of fatal coronary heart disease associated with diabetes in men and women: meta-analysis of 37 prospective cohort studies. BMJ. 2006;332:73–8.PubMedCentralPubMedCrossRefGoogle Scholar
  33. 33.
    Lee WL, Cheung AM, Cape D, Zinman B. Impact of diabetes on coronary artery disease in women and men: a meta-analysis of prospective studies. Diabetes Care. 2000;23:962–8.PubMedCrossRefGoogle Scholar
  34. 34.
    Donahue RP, Dorn JM, Stranges S, Swanson M, Hovey K, Trevisan M. Impaired fasting glucose and recurrent cardiovascular disease among survivors of a first acute myocardial infarction: evidence of a sex difference? The Western New York experience. Nutr Metabol Cardiovasc Dis. 2011;21:504–11.CrossRefGoogle Scholar
  35. 35.
    Leosdottir M, Willenheimer R, Persson M, Nilsson P. The association between glucometabolic disturbances, traditional cardiovascular risk factors and self-rated health by age and gender: a cross-sectional analysis within the Malmo Preventive Project. Cardiovasc Diabetol. 2011;10:118.PubMedCentralPubMedCrossRefGoogle Scholar
  36. 36.
    Levitan EB, Song Y, Ford ES, Liu S. Is nondiabetic hyperglycemia a risk factor for cardiovascular disease? A meta-analysis of prospective studies. Arch Intern Med. 2004;164:2147–55.PubMedCrossRefGoogle Scholar
  37. 37.
    Park S, Barrett-Connor E, Wingard DL, Shan J, Edelstein S. GHb is a better predictor of cardiovascular disease than fasting or postchallenge plasma glucose in women without diabetes. The Rancho Bernardo study. Diabetes Care. 1996;19:450–6.PubMedCrossRefGoogle Scholar
  38. 38.
    Kim SH, Reaven G. Sex differences in insulin resistance and cardiovascular disease risk. J Clin Endocrinol Metab. 2013;98:E1716–21.PubMedCentralPubMedCrossRefGoogle Scholar
  39. 39.
    Gerstein HC, Islam S, Anand S, et al. Dysglycaemia and the risk of acute myocardial infarction in multiple ethnic groups: an analysis of 15,780 patients from the INTERHEART study. Diabetologia. 2010;53:2509–17.PubMedCrossRefGoogle Scholar
  40. 40.
    Pan XR, Li GW, Hu YH, et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care. 1997;20:537–44.PubMedCrossRefGoogle Scholar
  41. 41.
    Chiasson JL, Josse RG, Gomis R, et al. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet. 2002;359:2072–7.PubMedCrossRefGoogle Scholar
  42. 42.
    Gerstein HC, Yusuf S, Bosch J, et al. The DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet. 2006;368:1096–105.PubMedCrossRefGoogle Scholar
  43. 43.
    Li G, Zhang P, Wang J, et al. The long-term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20-year follow-up study. Lancet. 2008;371:1783–9.PubMedCrossRefGoogle Scholar
  44. 44.
    Uusitupa M, Peltonen M, Lindström J, et al. Ten-year mortality and cardiovascular morbidity in the Finnish Diabetes Prevention Study - secondary analysis of the randomized trial. PLoS One. 2009;4:e5656.PubMedCentralPubMedCrossRefGoogle Scholar
  45. 45.
    Goldberg RB, Temprosa M, Haffner S, et al. Effect of progression from impaired glucose tolerance to diabetes on cardiovascular risk factors and its amelioration by lifestyle and metformin intervention: the Diabetes Prevention Program randomized trial by the Diabetes Prevention Program Research Group. Diabetes Care. 2009;32:726–32.PubMedCentralPubMedCrossRefGoogle Scholar
  46. 46.
    The Diabetes Prevention Program Outcomes Study Research Group, prepared on behalf of the DPPOS Research Group, Orchard TJ, et al. Long-term effects of the Diabetes Prevention Program interventions on cardiovascular risk factors: a report from the DPP Outcomes Study. Diabet Med. 2013;30:46–55.PubMedCentralPubMedCrossRefGoogle Scholar
  47. 47.
    The NAVIGATOR study group. Effect of valsartan on the incidence of diabetes and cardiovascular events. N Engl J Med. 2010;362:1477–90.CrossRefGoogle Scholar
  48. 48.
    The NAVIGATOR study group. Effect of nateglinide on the incidence of diabetes and cardiovascular events. N Engl J Med. 2010;362:1463–76.CrossRefGoogle Scholar
  49. 49.
    The DREAM Trial effects of ramipril and rosiglitazone on cardiovascular and renal outcomes in people with impaired glucose tolerance or impaired fasting glucose: results of the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) trial. Diabetes Care. 2008;31:1007–14.Google Scholar
  50. 50.
    The ORIGIN, Investigators T. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med. 2012;367:319–28.CrossRefGoogle Scholar
  51. 51.••
    Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA. 2003;290:486–94. This is the only diabetes prevention trial showing beneficial effects on CVD outcomes in individuals with prediabetes.PubMedCrossRefGoogle Scholar
  52. 52.
    Seifarth C, Bergmann J, Holst JJ, Ritzel R, Schmiegel W, Nauck MA. Prolonged and enhanced secretion of glucagon-like peptide 1 (7–36 amide) after oral sucrose due to alpha-glucosidase inhibition (acarbose) in Type 2 diabetic patients. Diabet Med. 1998;15:485–91.PubMedCrossRefGoogle Scholar
  53. 53.
    DeFronzo RA, Ferrannini E. Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care. 1998;14:173–94.CrossRefGoogle Scholar
  54. 54.
    Færch K, Bergman B, Perreault L. Does insulin resistance drive the association between hyperglycemia and cardiovascular risk? PLoS One. 2012;7:e39260.PubMedCentralPubMedCrossRefGoogle Scholar
  55. 55.
    Haffner SM, Mykkanen L, Festa A, Burke JP, Stern MP. Insulin-resistant prediabetic subjects have more atherogenic risk factors than insulin-sensitive prediabetic subjects: implications for preventing coronary heart disease during the prediabetic state. Circulation. 2000;101:975–80.PubMedCrossRefGoogle Scholar
  56. 56.
    Zhang Y, Lee ET, Howard BV, et al. Insulin resistance, incident cardiovascular diseases, and decreased kidney function among nondiabetic American Indians: the Strong Heart Study. Diabetes Care. 2013; [Epub ahead of print].Google Scholar
  57. 57.
    DeFronzo RA, Tripathy D, Schwenke DC, et al. Pioglitazone for diabetes prevention in impaired glucose tolerance. N Engl J Med. 2011;364:1104–15.PubMedCrossRefGoogle Scholar
  58. 58.
    Xiang AH, Hodis HN, Kawakubo M, et al. Effect of pioglitazone on progression of subclinical atherosclerosis in non-diabetic premenopausal Hispanic women with prior gestational diabetes. Atherosclerosis. 2008;199:207–14.PubMedCentralPubMedCrossRefGoogle Scholar
  59. 59.•
    Rydén L, Grant PJ, Anker SD, et al. ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). Eur Heart J. 2013; doi:10.1093/eurheartj/eht108. These guidelines represent the most up-to-date European recommendations on management of diabetes and prediabetes.
  60. 60.
    Ridker PM, Pradhan A, MacFadyen JG, Libby P, Glynn RJ. Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial. Lancet. 2011;380:565–71.CrossRefGoogle Scholar
  61. 61.
    D’Agostino RB, Vasan RS, Pencina MJ, et al. General cardiovascular risk profile for use in primary care. Circulation. 2008;117:743–53.PubMedCrossRefGoogle Scholar
  62. 62.
    Conroy RM, Pyorala K, Fitzgerald AP, et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J. 2003;24:987–1003.PubMedCrossRefGoogle Scholar
  63. 63.
    Anderson KM, Odell PM, Wilson PW, Kannel WB. Cardiovascular disease risk profiles. Am Heart J. 1991;121:293–8.PubMedCrossRefGoogle Scholar
  64. 64.
    Pencina MJ, D’Agostino Sr RB, Larson MG, Massaro JM, Vasan RS. Predicting the 30-year risk of cardiovascular disease: the Framingham Heart study. Circulation. 2009;119:3078–84.PubMedCentralPubMedCrossRefGoogle Scholar
  65. 65.
    Woodward M, Brindle P, Tunstall-Pedoe H. Adding social deprivation and family history to cardiovascular risk assessment: the ASSIGN score from the Scottish Heart Health Extended Cohort (SHHEC). Heart. 2007;93:172–6.PubMedCentralPubMedCrossRefGoogle Scholar
  66. 66.
    Hippisley-Cox J, Coupland C, Vinogradova Y, et al. Predicting cardiovascular risk in England and Wales: prospective derivation and validation of QRISK2. BMJ. 2008;336:1475–82.PubMedCentralPubMedCrossRefGoogle Scholar
  67. 67.
    Stevens RJ, Kothari V, Adler AI, Stratton IM. The UKPDS risk engine: a model for the risk of coronary heart disease in Type II diabetes (UKPDS 56). Clin Sci (Lond). 2001;101:671–9.CrossRefGoogle Scholar
  68. 68.
    Clarke PM, Gray AM, Briggs A, et al. A model to estimate the lifetime health outcomes of patients with type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model (UKPDS no. 68). Diabetologia. 2004;47:1747–59.PubMedCrossRefGoogle Scholar
  69. 69.
    Hayes AJ, Leal J, Gray AM, Holman RR, Clarke PM. UKPDS Outcomes Model 2: a new version of a model to simulate lifetime health outcomes of patients with type 2 diabetes mellitus using data from the 30 year United Kingdom Prospective Diabetes Study: UKPDS 82. Diabetologia. 2013;56:1925–33.PubMedCrossRefGoogle Scholar
  70. 70.
    Davis TM, Stratton IM, Fox CJ, Holman RR, Turner RC. U.K. Prospective Diabetes Study 22. Effect of age at diagnosis on diabetic tissue damage during the first 6 years of NIDDM. Diabetes Care. 1997;20:1435–41.PubMedCrossRefGoogle Scholar
  71. 71.
    Feher MD, Elkeles RS. Lipid modification and coronary heart disease in type 2 diabetes: different from the general population? Heart. 1999;81:10–1.PubMedCentralPubMedCrossRefGoogle Scholar
  72. 72.
    Grundy SM. Pre-diabetes, metabolic syndrome, and cardiovascular risk. J Am Coll Cardiol. 2012;59:635–43.PubMedCrossRefGoogle Scholar
  73. 73.
    Assmann G, Cullen P, Schulte H. Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the prospective cardiovascular Munster (PROCAM) study. Circulation. 2002;105:310–5.PubMedCrossRefGoogle Scholar
  74. 74.
    Ferrario M, Chiodini P, Chambless LE, et al. Prediction of coronary events in a low incidence population. Assessing accuracy of the CUORE Cohort Study prediction equation. Int J Epidemiol. 2005;34:413–21.PubMedCrossRefGoogle Scholar
  75. 75.
    Wu Y, Liu X, Li X, et al. Estimation of 10-year risk of fatal and nonfatal ischemic cardiovascular diseases in Chinese adults. Circulation. 2006;114:2217–25.PubMedCrossRefGoogle Scholar
  76. 76.
    Braun J, Bopp M, Faeh D. Blood glucose may be an alternative to cholesterol in CVD risk prediction charts. Cardiovasc Diabetology. 2013;12. doi:10.1186/1475-2840-12-24.
  77. 77.
    The DECODE Study Group. Prediction of the risk of cardiovascular mortality using a score that includes glucose as a risk factor. The DECODE Study. Diabetologia. 2004;47(12);2118–28.Google Scholar
  78. 78.
    The DECODE Study Group. Is the current definition for diabetes relevant to mortality risk from all causes and cardiovascular and noncardiovascular diseases? Diabetes Care. 2003;26:688–96.CrossRefGoogle Scholar
  79. 79.
    Bartnik M, Ryden L, Ferrari R, et al. The prevalence of abnormal glucose regulation in patients with coronary artery disease across Europe. The Euro Heart Survey on diabetes and the heart. Eur Heart J. 2004;25:1880–90.PubMedCrossRefGoogle Scholar
  80. 80.
    Schöttker B, Müller H, Rothenbacher D, Brenner H. Fasting plasma glucose and HbA1c in cardiovascular risk prediction: a sex-specific comparison in individuals without diabetes mellitus. Diabetologia. 2013;56:92–100.PubMedCrossRefGoogle Scholar
  81. 81.
    Streiner DL. Breaking up is hard to do: the heartbreak of dichotomizing continuous data. Can J Psychiatry. 2002;47:262–6.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  • Kristine Færch
    • 1
  • Dorte Vistisen
    • 1
  • Nanna Borup Johansen
    • 1
  • Marit Eika Jørgensen
    • 1
  1. 1.Steno Diabetes Center A/SNiels Steensens Vej 2GentofteDenmark

Personalised recommendations